

# Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants

NCT07437105

---

Status	RECRUITING
Phase	Phase 1
Sponsor	Vertex Pharmaceuticals Incorporated
Enrollment	128 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square ( $\text{kg}/\text{m}^2$ )
- A total body weight of more than ( $>$ ) 50 kg
- Male and Female participants of non-childbearing potential

### Exclusion (2)

- History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
- Any condition possibly affecting drug absorption

## Locations (1 total)

---

Celerion - Tempe, Tempe, Arizona, United States